RxDoctor Payments DataLook up a doctor →

Theofanis Mitsinikos, DO

Endocrinology, Diabetes & Metabolism · Stony Brook, NYNPI 1467624064

Payments from drug & device makers

$156,731in general payments, 2019–2025

Across 1,458 payments — averaging $107.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$34K
  • Mannkind Corporation$24K
  • AbbVie$22K
  • Intra-sana Laboratories$14K
  • Sanofi-aventis U.S. LLC$13K
  • Amarin Pharma, Inc.$13K
  • plus $37K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)115$34,150
Mannkind Corporation121$23,966
AbbVie94$22,208
Intra-sana Laboratories26$14,444
Sanofi-aventis U.S. LLC113$12,626
Amarin Pharma, Inc.88$12,543
Intuity Medical Inc18$6,994
Lilly USA, LLC83$6,681
Novo Nordisk158$3,010
Amgen(2 entities)103$2,748
IBSA Pharma Inc.17$2,481
Johnson & Johnson8$2,472
Boehringer Ingelheim56$1,683
Xeris Pharmaceuticals, Inc.48$1,217
Medtronic(2 entities)37$970
Bayer41$755
Dexcom, Inc.16$681
Corcept Therapeutics27$609
Vivus LLC29$583
Cvrx, Inc.3$569
Amneal Pharmaceuticals LLC35$553
Abbott27$530
Ascendis Pharma Endocrinology Inc7$463
Insulet Corporation13$396
Ipsen Biopharmaceuticals, Inc8$292
Novartis15$288
Endo Pharmaceuticals Inc.15$266
Merck15$225
Radius Health, Inc.12$214
Esperion Therapeutics, Inc.11$188
Recordati_rare_diseases_inc.7$170
Kowa Pharmaceuticals America, Inc.9$148
Pfizer5$125
Currax Pharmaceuticals LLC7$119
Lifescan, Inc.6$113
Antares Pharma, Inc.6$113
Eisai Inc.5$103
Aytu Biopharma, Inc.6$101
Tandem Diabetes Care, Inc.6$100
Verity Pharmaceuticals Inc.6$99
Madrigal Pharmaceuticals3$85
Clarus Therapeutics Inc.4$82
Shire North American Group Inc3$75
Ascensia Diabetes Care US Inc.2$63
Ultragenyx Pharmaceutical Inc.3$56
BD2$44
Endo USA, Inc.2$42
GSK2$39
Cequr Corporation2$39
Amryt Pharma Holdings Ltd2$36
Nevro Corp.2$35
Zealand Pharma US, Inc.1$20
Almatica Pharma LLC1$19
Nalpropion Pharmaceuticals LLC1$18
Astellas Pharma US Inc1$17
Chiesi USA, Inc.1$15
Kyowa Kirin, Inc.1$14
Regeneron Healthcare Solutions, Inc.1$14
Covidien LP1$13
Companion Medical, Inc.1$12

How this compares

$156,731 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024
$840,911
Medicare patients
1,212
Services billed
40,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Stony Brook

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →